← FDA DRUG APPROVALS

FDA ANDA · ANDA078967

NICOTINE POLACRILEX

Sponsor: PERRIGO R AND D

APPLICATION
ANDA078967
TYPE
ANDA
ORIGINAL APPROVAL
2008-04-23
LATEST ACTION
2024-03-27
ROUTE
BUCCAL
DOSAGE FORM
GUM, CHEWING
MARKETING STATUS
Discontinued

Products

NICOTINE POLACRILEXDiscontinued
NICOTINE POLACRILEX EQ 2MG BASE · GUM, CHEWING · BUCCAL

Approval history

2024-03-27Labeling · Supplement 11 · standardAP
2024-03-27Labeling · Supplement 14 · standardAP
2012-11-29Labeling · Supplement 9 · standardAP
2010-06-17Labeling · Supplement 5AP
2008-04-23OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →